Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
TRYP Therapeutics Doses First Patients in Phase 2 Psilocybin Trial
Phase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder. “The world’s first FDA regulated clinical trial for psilocybin-assisted therapy targeting BED is underway, further advancing our clinical milestones,” said Dr. Jim Gilligan, Chief Scientific Officer, and interim CEO of Tryp Therapeutics.
Field Trip to Split Into Two Independent Public Companies
Field Trip Discovery will be renamed Reunion Neuroscience Inc. and Field Trip Health will be renamed Field Trip Health and Wellness Ltd. The transaction will create two distinct companies, one providing personalized care and the other developing next generation psychedelic therapies. Shareholders of Field Trip will receive shares of each company.
Numinus Announces the Music as Medicine Event Series
Numinus announced the launching of Music As Medicine by Numinus, a series of ceremonial concerts exploring the role music plays in psychedelic-assisted therapy and mental health. Music As Medicine by Numinus will feature a rotating roster of meditative and ambient musicians, including Jon Hopkins, East Forest and Superposition, multimedia art, and immersive guided meditations.
Phyto Partners Launches Neurowellness-Focused Venture Capital Fund
Phyto Partners has partnered with Ambria Capital to launch a fund focused on businesses operating in and around neurowellness and brain health and the use of psychedelic compounds.
Filament Health Granted Its Fourth Patent
Filament Health announced that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds.
“Adding a fourth patent to our portfolio demonstrates the calibre of Filament’s intellectual property strategy and drug development platform,” said Ryan Moss, Chief Science Officer at Filament Health. “Our ability to transform valuable natural substances into IP-protected pharmaceutical-grade drug candidates sets us apart as industry leaders.”
PharmaTher Reports Q3 Financial and Business Highlights
PharmaTher continues to be one of those under-the-radar firms, consistently putting out positive news and moving its pipeline forward. Here are some highlights from its Q3 results:
- Nearly $12 million in cash and investment
- Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders
- Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation
